Nanotechnology May Enable Detection of Biomarkers, Facilitate Cancer Diagnosis

Share this content:

A new technology detects disease biomarkers in the form of nucleic acids, which are the molecules that comprise DNA and RNA.1

"We envision this as a potential first-line, noninvasive diagnostic to detect anything from cancer to the Ebola virus," said Adam R. Hall, PhD, assistant professor of biomedical engineering at Wake Forest Baptist Medical Center in Winston-Salem, North Carolina, and lead author of the study. "Although we are certainly at the early stages of the technology, eventually we could perform the test using a few drops of blood from a simple finger prick."

The test is zeroing in on microRNA, or sequences of RNA that are only approximately 20 bases long. MicroRNAs can signal a wide range of diseases, including cancer.

Continue Reading Below

"Scientists have studied microRNA biomarkers for years, but one problem has been accurate detection because they are so short, many technologies have real difficulty identifying them," Hall explained.

This new technique uses nanotechnology to determine if a specific target nucleic acid sequence exists within a mixture. If it does, then it is quantified through a simple electronic signature.

"If the sequence you are looking for is there, it forms a double helix with a probe we provide and you see a clear signal. If the sequence isn't there, then there isn't any signal," Hall said. "By simply counting the number of signals, you can determine how much of the target is around."

The first step in this study was to demonstrate that this technology could effectively identify a specific sequence among a background of competing nucleic acids. Next, this approach was applied to mi-R155, which is a particular microRNA known to indicate lung cancer in humans. The research team demonstrated that the approach could resolve the minute amount of microRNAs that can be found in patients. Next steps will involve expanding the technology to study clinical samples of blood, tissue, or urine.

Hall holds a provisional patent on this technology.

Continue Reading Below


1. Zahid OK, Wang F, Ruzicka JA, et al. Sequence-specific recognition of microRNAs and other short nucleic acids with solid-state nanopores [published online ahead of print January 29, 2016]. Nano Lett. doi:10.1021/acs.nanolett.6b00001.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs